Allakos Inc. (NASDAQ:ALLK) Short Interest Update

Allakos Inc. (NASDAQ:ALLK - Get Free Report) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 842,800 shares, a drop of 15.7% from the November 30th total of 1,000,000 shares. Based on an average daily volume of 656,500 shares, the days-to-cover ratio is presently 1.3 days.

Allakos Stock Up 3.2 %

ALLK traded up $0.04 during trading on Friday, hitting $1.30. The company had a trading volume of 250,605 shares, compared to its average volume of 789,747. The company has a market capitalization of $116.15 million, a PE ratio of -0.64 and a beta of 0.92. Allakos has a one year low of $0.54 and a one year high of $3.36. The firm's 50-day moving average price is $1.16 and its 200 day moving average price is $0.91.

Allakos (NASDAQ:ALLK - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.01. Sell-side analysts forecast that Allakos will post -1.16 earnings per share for the current year.

Institutional Investors Weigh In On Allakos

Several institutional investors have recently bought and sold shares of the company. Point72 Asset Management L.P. acquired a new stake in shares of Allakos in the third quarter valued at approximately $1,143,000. FMR LLC increased its stake in Allakos by 14.6% in the 3rd quarter. FMR LLC now owns 5,370,247 shares of the company's stock valued at $3,508,000 after buying an additional 685,623 shares during the last quarter. Acadian Asset Management LLC lifted its position in Allakos by 32.4% during the 2nd quarter. Acadian Asset Management LLC now owns 1,762,814 shares of the company's stock worth $1,761,000 after buying an additional 431,175 shares in the last quarter. RBF Capital LLC boosted its stake in shares of Allakos by 45.9% during the 3rd quarter. RBF Capital LLC now owns 510,529 shares of the company's stock worth $333,000 after buying an additional 160,529 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Allakos in the 2nd quarter valued at about $112,000. Institutional investors own 84.64% of the company's stock.

Analysts Set New Price Targets

Separately, JMP Securities reiterated a "market outperform" rating and issued a $3.00 price objective on shares of Allakos in a research report on Thursday, September 26th.

About Allakos

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.